HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results – Interim analysisSantam Chakraborty, Debdeep Dey, Sanjoy Chatterjee et al.|Radiotherapy and Oncology|2022Cited by 42
Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)—study protocol for a multicentre, randomized phase III trialSanjoy Chatterjee, Santam Chakraborty, Selvamani Backianathan et al.|Trials|2020Cited by 29
P4.11D.04 A Phase 1/2 Study of REGN7075 (EGFRÃ-CD28) Combined with Cemiplimab (anti-PD-1) In NSCLC: Trial in Progress UpdateM.L. Johnson, Neil H. Segal, L. Fong et al.|Journal of Thoracic Oncology|2024Cited by 0